2006 Volume 48 Issue 4 Pages 315-324
To determine the efficacy of probiotics on periodontal diseases, Lactobacillus salivarius TI2711 (LS1) was orally administered to volunteers. The 87 subjects were divided into two administration (n=49) and one placebo (n=38) group. Administration groups took either 2x108 (n=39) a day for 12 weeks. At baseline, 4 and 12 weeks after LS1 administration and 4 weeks after the termination of LS1 administration (at week 16), subjects were clinical by examied for probing depth (PD), bleeding on probing (BOP), and plaque control record (PCR), and, subgingival plaque samples were collected from all subjects to measure the number of Porphyromonas gingivalis and L. salivarius bacteria in plaque using real-time PCR. A significant reduction in the number of P. gingivalis bacteria was found in the administration group from 1.12x105 to 2.97x104 at 12 weeks(P<0.05), but, not at week 16 compared to baseline. The number of L. salivarius bacteria increased at 4 and 12 weeks and decreased at week 16. No significant change in the number of L. salivarius bacteria was observed in the placebo group. These results imply a reverse correlation between the numbers of P. gingivalis and LS1. This means that LS1 translocates to subgingival plaque, then decreased the number of P. gingivalis. This data also suggests that LS1 is an effective probiotic. Nihon Shishubyo Gakkai Kaishi (J Jpn Soc Periodontol) 48 : 315-324, 2006.
